What's in Myeong Jun Song's pipeline?

Myeong Jun Song has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Myeong Jun Song's portfolio?

Top competitors by shared drug class: Dallas VA Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/myeong-jun-song.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Myeong Jun Song — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myeong Jun Song pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Daclatasvir plus Asunaprevir	Daclatasvir plus Asunaprevir	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease	Infectious Disease (Hepatology)

Therapeutic area mix

Infectious Disease (Hepatology) · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dallas VA Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Myeong Jun Song:

Cite this brief

Drug Landscape (2026). Myeong Jun Song — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/myeong-jun-song. Accessed 2026-05-16.